JP2001517425A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001517425A5 JP2001517425A5 JP2000512857A JP2000512857A JP2001517425A5 JP 2001517425 A5 JP2001517425 A5 JP 2001517425A5 JP 2000512857 A JP2000512857 A JP 2000512857A JP 2000512857 A JP2000512857 A JP 2000512857A JP 2001517425 A5 JP2001517425 A5 JP 2001517425A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- kda
- lymphocytes
- activated
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 description 52
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 24
- 230000000139 costimulatory effect Effects 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 108090000765 processed proteins & peptides Proteins 0.000 description 18
- 230000004071 biological effect Effects 0.000 description 17
- 230000000284 resting effect Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 12
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 210000003714 granulocyte Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940039227 diagnostic agent Drugs 0.000 description 3
- 239000000032 diagnostic agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000004848 nephelometry Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19741929 | 1997-09-23 | ||
| DE19741929.1 | 1997-09-23 | ||
| DE19821060.4 | 1998-05-11 | ||
| DE19821060A DE19821060A1 (de) | 1997-09-23 | 1998-05-11 | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| PCT/DE1998/002896 WO1999015553A2 (de) | 1997-09-23 | 1998-09-23 | Ko-stimulierendes polypeptid von t-zellen, monoklonale antikörper sowie die herstellung und deren verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009211970A Division JP5021008B2 (ja) | 1997-09-23 | 2009-09-14 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001517425A JP2001517425A (ja) | 2001-10-09 |
| JP2001517425A5 true JP2001517425A5 (enExample) | 2006-01-05 |
| JP4463418B2 JP4463418B2 (ja) | 2010-05-19 |
Family
ID=26040229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000512857A Expired - Fee Related JP4463418B2 (ja) | 1997-09-23 | 1998-09-23 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7259247B1 (enExample) |
| EP (1) | EP1017723B1 (enExample) |
| JP (1) | JP4463418B2 (enExample) |
| AU (1) | AU752433B2 (enExample) |
| CA (1) | CA2305350C (enExample) |
| DE (1) | DE59813875D1 (enExample) |
| ES (1) | ES2279585T3 (enExample) |
| WO (1) | WO1999015553A2 (enExample) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| JP4463418B2 (ja) | 1997-09-23 | 2010-05-19 | ドイツ連邦共和国 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
| DE19821060A1 (de) | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| CA2346496A1 (en) * | 1998-10-07 | 2000-04-13 | Millennium Pharmaceuticals, Inc. | Novel th2-specific molecules and uses thereof |
| US7435796B1 (en) | 1999-02-03 | 2008-10-14 | Amgen Inc. | Antibodies which bind B7RP1 |
| US8624010B1 (en) | 1999-02-03 | 2014-01-07 | Steven K. Yoshinaga | Nucleic acids encoding B7RP1 |
| WO2000046240A2 (en) * | 1999-02-03 | 2000-08-10 | Amgen Inc. | Polypeptides involved in immune response |
| US7708993B2 (en) * | 1999-02-03 | 2010-05-04 | Amgen Inc. | Polypeptides involved in immune response |
| WO2001012658A2 (en) * | 1999-08-11 | 2001-02-22 | Isis Innovations Limited | Human icos ligand and application thereof |
| JP3871503B2 (ja) * | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) * | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| EP1218504B1 (en) | 1999-09-21 | 2007-07-11 | Genetics Institute, LLC | Gl50 molecules and uses therefor |
| EP1900816A3 (en) * | 1999-09-21 | 2008-03-26 | Genetics Institute, LLC | GL50 molecules and uses therefor |
| JP3597140B2 (ja) * | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途 |
| AU2002217969B2 (en) * | 2000-11-28 | 2007-12-20 | Amgen Canada Inc. | Polypeptides involved in immune response |
| AU2002308267A1 (en) * | 2001-01-16 | 2002-10-03 | Bayer Aktiengesellschaft | Regulation of human icos v protein |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| EP1740617B1 (en) | 2004-04-23 | 2013-10-16 | BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten | Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| BR112013006718B1 (pt) | 2010-09-20 | 2021-12-07 | Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberguniversität Mainz Gemeinnutzige Gmbh | Receptor de células t com especificidade para ny-eso-1, composição farmacêutica compreendendo o mesmo e uso do mesmo |
| US9376493B2 (en) * | 2011-03-31 | 2016-06-28 | INSERM (Institut National de la Sante et de la Recherche Mediacale) | Antibodies directed against ICOS and uses thereof |
| US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
| PH12022550138A1 (en) | 2013-03-13 | 2023-03-06 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
| HRP20201113T1 (hr) | 2013-03-15 | 2020-10-30 | Glaxosmithkline Intellectual Property Development Limited | Vežući proteini protiv lag-3 |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| KR20170129902A (ko) | 2015-03-23 | 2017-11-27 | 조운스 테라퓨틱스, 인크. | Icos에 대한 항체 |
| RU2021133819A (ru) | 2015-09-02 | 2021-12-10 | Иммутеп С.A.С. | Анти-lag-3 антитела |
| KR20180066236A (ko) | 2015-10-22 | 2018-06-18 | 조운스 테라퓨틱스, 인크. | Icos 발현을 계측하기 위한 유전자 특질 |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| EP3497128A2 (en) | 2016-08-09 | 2019-06-19 | Kymab Limited | Anti-icos antibodies |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| BR112020018539A2 (pt) | 2018-03-23 | 2020-12-29 | Bristol-Myers Squibb Company | Anticorpos contra mica e/ou micb e usos dos mesmos |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2020243563A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| CN114174537A (zh) | 2019-05-30 | 2022-03-11 | 百时美施贵宝公司 | 细胞定位特征和组合疗法 |
| EP4534075A3 (en) | 2019-10-28 | 2025-12-17 | MedImmune Limited | Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
| IL300916A (en) | 2020-08-31 | 2023-04-01 | Bristol Myers Squibb Co | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
| WO2022146947A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| EP4531916A1 (en) | 2022-06-02 | 2025-04-09 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024054992A1 (en) | 2022-09-09 | 2024-03-14 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| CN121712571A (zh) | 2023-08-15 | 2026-03-20 | 百时美施贵宝公司 | 陶瓷羟基磷灰石色谱流通法 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8801537D0 (sv) | 1988-04-26 | 1988-04-26 | Ellco Food Ab | Cellodlingsmedium samt forfarande for dess framstellning |
| WO1990004180A1 (en) * | 1988-10-06 | 1990-04-19 | T Cell Sciences, Inc. | Therapeutic and diagnostic methods using soluble t cell surface molecules |
| US7112655B1 (en) * | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
| JP3521382B2 (ja) * | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
| DE19821060A1 (de) * | 1997-09-23 | 1999-04-15 | Bundesrepublik Deutschland Let | Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung |
| JP4463418B2 (ja) | 1997-09-23 | 2010-05-19 | ドイツ連邦共和国 | Ｔ細胞共同刺激性ポリペプチド、モノクローナル抗体、ならびにその製法および使用 |
-
1998
- 1998-09-23 JP JP2000512857A patent/JP4463418B2/ja not_active Expired - Fee Related
- 1998-09-23 WO PCT/DE1998/002896 patent/WO1999015553A2/de not_active Ceased
- 1998-09-23 ES ES98956800T patent/ES2279585T3/es not_active Expired - Lifetime
- 1998-09-23 US US09/509,283 patent/US7259247B1/en not_active Expired - Lifetime
- 1998-09-23 AU AU13320/99A patent/AU752433B2/en not_active Ceased
- 1998-09-23 DE DE59813875T patent/DE59813875D1/de not_active Expired - Lifetime
- 1998-09-23 CA CA2305350A patent/CA2305350C/en not_active Expired - Lifetime
- 1998-09-23 EP EP98956800A patent/EP1017723B1/de not_active Expired - Lifetime
-
2007
- 2007-10-23 US US11/977,335 patent/US20080118513A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001517425A5 (enExample) | ||
| JP2010042007A5 (enExample) | ||
| Fanger et al. | Cytotoxicity mediated by human Fc receptors for IgG | |
| Larrubia et al. | Role of chemokines and their receptors in viral persistence and liver damage during chronic hepatitis C virus infection | |
| Tanaka et al. | Fas ligand in human serum | |
| Singer et al. | CCR5, CXCR4, and CD4 are clustered and closely apposed on microvilli of human macrophages and T cells | |
| Hasegawa et al. | Increased chemokine receptor CCR7/EBI1 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells | |
| Murai et al. | Active participation of CCR5+ CD8+ T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease | |
| Auerbach et al. | Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor | |
| Uppaluri et al. | Prolongation of cardiac and islet allograft survival by a blocking hamster anti-mouse CXCR3 monoclonal antibody | |
| Montefiori et al. | Evidence that antibody-mediated neutralization of human immunodeficiency virus type 1 by sera from infected individuals is independent of coreceptor usage | |
| Riley et al. | Naıve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implications for transmission and pathogenesis | |
| Odobasic et al. | Distinct in vivo roles of CD80 and CD86 in the effector T‐cell responses inducing antigen‐induced arthritis | |
| CA2011893A1 (en) | Pharmaceutical product for the treatment of immunoregulatory disorders | |
| Cuthbert et al. | Immunological studies in HIV seronegative haemophiliacs: relationships to blood product therapy | |
| Wakefield et al. | Distribution of lymphocytes and cell adhesion molecules in iris biopsy specimens from patients with uveitis | |
| Müller‐Ladner et al. | Progressive joint destruction in a human immunodeficiency virus‐infected patient with rheumatoid arthritis | |
| Speth et al. | Complement receptors in HIV infection | |
| Lehner et al. | Induction of inhibitory antibodies to the CCR5 chemokine receptor and their complementary role in preventing SIV infection in macaques | |
| Yoshie et al. | Interferon action: Effects of mouse α and β interferons on rosette formation, phagocytosis, and surface-antigen expression of cells of the macrophage-type line RAW 309Cr. 1 | |
| Zeiser | Biology-driven developments in the therapy of acute graft-versus-host disease | |
| Vermeire et al. | Specific CD4 down-modulating compounds with potent anti-HIV activity | |
| WO1995007716A1 (en) | Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon | |
| Tanaka et al. | Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection | |
| Starling et al. | Inhibition of natural killer-cell mediated cytolysis with monoclonal antibodies to restricted and non-restricted epitopes of the leucocyte common antigen |